BR0214224A - Derivado de 4,4-diflúor-1,2,3,4-tetrahidro-5h-1-benzazepina ou sal do mesmo - Google Patents

Derivado de 4,4-diflúor-1,2,3,4-tetrahidro-5h-1-benzazepina ou sal do mesmo

Info

Publication number
BR0214224A
BR0214224A BR0214224-4A BR0214224A BR0214224A BR 0214224 A BR0214224 A BR 0214224A BR 0214224 A BR0214224 A BR 0214224A BR 0214224 A BR0214224 A BR 0214224A
Authority
BR
Brazil
Prior art keywords
lower alkyl
aromatic heterocycle
salt
difluoro
tetrahydro
Prior art date
Application number
BR0214224-4A
Other languages
English (en)
Inventor
Hiroyuki Koshio
Issei Tsukamoto
Takahiro Kuramochi
Seijiro Akamatsu
Chikashi Saitoh
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of BR0214224A publication Critical patent/BR0214224A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"DERIVADO DE 4,4-DIFLúOR-1,2,3,4-TETRAHIDRO-5H-1-BENZAZEPINA OU SAL DO MESMO". A presente invenção proporciona um excelente agente terapêutico para diabetes central insipidus e/ou nocturia. A invenção refere-se a um derivado de 4,4-diflúor-1,2,3,4-tetrahidro-5H-1-benzazepina representado pela Fórmula geral (I) ou um sal farmaceuticamente aceitável do mesmo: em que os símbolos têm os seguintes significados: R^ 1^:-OH,-O-alquila inferior ou -NR^ 11^R^ 12^, R^ 2^: alquila inferior que pode ser substituída com um ou mais átomos de halogênio ou halogênio, R^ 3^ e R^ 4^ : heterociclo aromático ou heterociclo não-aromático, cada um dos quais pode ser substituído, juntamente com o átomo de nitrogênio adjacente, R^ 5^: -H, alquila inferior ou halogênio, R^ 11^ e R^ 12^: (1) que pode ser idêntico ou diferente, -H; arila ou heterociclo aromático opcionalmente substituído; -CO-alquila inferior; ou -SO~ 2~-alquila inferior ou (2) heterociclo não-aromático opcionalmente substituído, juntamente com o átomo de nitrogênio adjacente.
BR0214224-4A 2001-11-16 2002-11-13 Derivado de 4,4-diflúor-1,2,3,4-tetrahidro-5h-1-benzazepina ou sal do mesmo BR0214224A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001350909 2001-11-16
JP2002252931 2002-08-30
PCT/JP2002/011842 WO2003042181A1 (fr) 2001-11-16 2002-11-13 Derives de 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine, ou sels desdits derives

Publications (1)

Publication Number Publication Date
BR0214224A true BR0214224A (pt) 2004-09-21

Family

ID=26624548

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214224-4A BR0214224A (pt) 2001-11-16 2002-11-13 Derivado de 4,4-diflúor-1,2,3,4-tetrahidro-5h-1-benzazepina ou sal do mesmo

Country Status (17)

Country Link
US (1) US7169772B2 (pt)
EP (1) EP1445253B1 (pt)
JP (1) JP4075064B2 (pt)
KR (1) KR100632882B1 (pt)
CN (1) CN1323076C (pt)
AT (1) ATE438626T1 (pt)
AU (1) AU2002349773B2 (pt)
BR (1) BR0214224A (pt)
CA (1) CA2464069A1 (pt)
DE (1) DE60233251D1 (pt)
ES (1) ES2327620T3 (pt)
HU (1) HUP0402235A2 (pt)
MX (1) MXPA04004501A (pt)
NO (1) NO20042497L (pt)
PL (1) PL369999A1 (pt)
RU (1) RU2268882C1 (pt)
WO (1) WO2003042181A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
JP2006508339A (ja) 2002-09-20 2006-03-09 プロメガ　コーポレイション シトクロムｐ４５０活性を測定するための発光を利用する方法およびプローブ
WO2004047730A2 (en) * 2002-11-21 2004-06-10 New York Blood Center Compounds for inhibition of hiv infection by blocking hiv entry
ATE512951T1 (de) 2003-04-28 2011-07-15 Astellas Pharma Inc 4,4-difluor-1,2,3,4-tetrahydro-5h-1- benzazepinderivat oder salz davon
WO2005090282A1 (en) 2004-03-12 2005-09-29 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
WO2006130551A2 (en) 2005-05-31 2006-12-07 Promega Corporation Luminogenic and fluorogenic compounds and methods to detect molecules or conditions
EP1935986B1 (en) 2005-05-31 2014-04-16 Promega Corporation Luminogenic and fluorogenic compounds and methods to detect molecules or conditions
ES2531621T3 (es) 2005-07-22 2015-03-18 Mochida Pharmaceutical Co., Ltd. Derivado de heterociclidenacetamida novedoso
JP5164510B2 (ja) * 2006-10-06 2013-03-21 日本曹達株式会社 含窒素複素環化合物および有害生物防除剤
TW200835502A (en) 2006-12-26 2008-09-01 Daiichi Sankyo Co Ltd Thiazepine derivatives
US20100016285A1 (en) * 2007-01-24 2010-01-21 Mochida Pharmaceutical Co., Ltd. Heterocyclidene-n-(aryl) acetamide derivative
PE20081692A1 (es) 2007-01-24 2008-12-18 Mochida Pharm Co Ltd Nuevo derivado de heterocicliden acetamida
US8227500B2 (en) 2007-04-11 2012-07-24 Kissei Pharmaceutical Co., Ltd. 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same
EP2197532A1 (en) 2007-08-06 2010-06-23 Serenity Pharmaceuticals Corporation Methods and devices for desmopressin drug delivery
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
WO2009143356A1 (en) * 2008-05-21 2009-11-26 Ferring International Center S.A. Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia
UY32940A (es) 2009-10-27 2011-05-31 Bayer Cropscience Ag Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas
DK2860175T3 (da) 2012-06-11 2018-01-29 Tacurion Fremgangsmåde til fremstilling af 4,4,7-trifluor-1,2,3,4-tetrahydro-5h-1-benzazepin-forbindelse og intermediat til syntese deraf
RU2642783C2 (ru) * 2012-12-26 2018-01-26 Санва Кагаку Кенкюсо Ко., Лтд. Новое производное бензоазепина и его медицинское применение
US9790537B2 (en) 2014-01-29 2017-10-17 Promega Corporation Quinone-masked probes as labeling reagents for cell uptake measurements
CN105310978A (zh) * 2014-08-04 2016-02-10 李峰 一种含有活性成分盐酸考尼伐坦的药物组合物及其制剂
CN112079826B (zh) * 2020-09-17 2022-07-29 广州中医药大学(广州中医药研究院) 一类甾体合成酶抑制剂及其治疗应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1039999A (zh) * 1988-07-30 1990-02-28 刘晓非 多层复合装饰板及制作方法
TW270927B (pt) 1992-10-16 1996-02-21 Otsuka Pharma Co Ltd
PL182011B1 (en) * 1993-08-26 2001-10-31 Yamanouchi Pharma Co Ltd Benzazepine derivative, pharmaceutic composition and intermediate compounds
TW359669B (en) 1995-12-15 1999-06-01 Otsuka Pharma Co Ltd Benzazepine derivatives
JPH09221475A (ja) * 1996-02-13 1997-08-26 Yamanouchi Pharmaceut Co Ltd 新規なオキシム誘導体
AR011913A1 (es) 1997-03-06 2000-09-13 Yamano Masaki Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos.

Also Published As

Publication number Publication date
MXPA04004501A (es) 2004-08-11
CN1585752A (zh) 2005-02-23
KR100632882B1 (ko) 2006-10-13
JPWO2003042181A1 (ja) 2005-03-10
HUP0402235A2 (hu) 2005-02-28
AU2002349773B2 (en) 2007-12-13
US20050004103A1 (en) 2005-01-06
RU2004118063A (ru) 2006-01-10
RU2268882C1 (ru) 2006-01-27
CN1323076C (zh) 2007-06-27
ES2327620T3 (es) 2009-11-02
US7169772B2 (en) 2007-01-30
EP1445253A1 (en) 2004-08-11
PL369999A1 (en) 2005-05-16
KR20050044401A (ko) 2005-05-12
EP1445253B1 (en) 2009-08-05
EP1445253A4 (en) 2005-11-16
WO2003042181A1 (fr) 2003-05-22
NO20042497L (no) 2004-07-21
JP4075064B2 (ja) 2008-04-16
CA2464069A1 (en) 2003-05-22
ATE438626T1 (de) 2009-08-15
DE60233251D1 (de) 2009-09-17

Similar Documents

Publication Publication Date Title
BR0214224A (pt) Derivado de 4,4-diflúor-1,2,3,4-tetrahidro-5h-1-benzazepina ou sal do mesmo
BRPI0512985A (pt) derivados de 3-carbamoil-2-piridona
BR0206670A (pt) Compostos halogenados que exibem agonismo para receptor de trombopoietina
BR0210028A (pt) Agentes antibacterianos
BR0308696A (pt) Derivados de quinolina e seu emprego como ligante de 5-ht6
BRPI0407976A (pt) tetrahidroisoquinolinas substituìdas em 2,5 e 2,6 para uso como moduladores de 5-ht6
BR0212760A (pt) Compostos quìmicos
BRPI0417771A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóides
BR0309664A (pt) Derivados de [1,4]diazepino[6,7,1-ij]quinolina como agentes anti-psicóticos e antiobesidade
BRPI0212894B8 (pt) composto ou sal do mesmo farmaceuticamente aceitável e composição farmacêutica
BR0211206A (pt) Derivados de 8-metóxi-(1,2,4)triazolo(1, 5-a)piridina e seus usos como ligantes do receptor de adenosina
BR0012697A (pt) Inibidores da diferenciação de th2
MA29213B1 (fr) Quinolones a substitution macrolones - amino
EP1362846A4 (en) AMINOETHANOLDERIVATE
BR0210874A (pt) Derivados de tiazol-benzamida e composições farmacêuticas para a inibição da proliferação celular e métodos para o seu uso
BR9905788A (pt) Derivados de 2-(2-oxo-etilideno)-imidazolidin-4-ona e composições e métodos para a inibição do crescimento de célula anormal que compreendem os referidos derivados
BR0210538A (pt) Derivados de 5-halotriptamina usados como ligantes dos receptores de serotonina 5-ht6 e/ou 5-ht7
TW200716650A (en) Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-met autophosphorylation inhibiting potency
BR9808552A (pt) Composto tricìclico ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
BRPI0411285A (pt) composto, processo para preparar um composto formulação farmacêutica, uso de um composto, e, método de prevenção ou tratamento de distúrbios
BR0313846A (pt) Derivados de dioxano-2-alquilcarbamatos, sua preparação e sua aplicação em terapêutica
BR0308338A (pt) Derivados de nitrosodifenilamina e seu uso farmacêutico contra patologias de estresse oxidativo
BR9807079A (pt) Composto de derivado de 16-hidróxi-11- (fenil substituìdo) - estra-4,9-dieno, uso de um composto, formulação farmacêutica, e processo para a preparação de um composto.
BR0113389A (pt) Compostos que inibem a atividade do fator xa
BRPI0411723A (pt) agente redutor de colesterol no soro ou agente preventivo ou terapêutico para aterosclerose, e, método de dosagem de um agente redutor de colesterol no soro ou agente preventivo ou terapêutico para aterosclerose

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: ASTELLAS PHARMA INC. (JP)

Free format text: ALTERADO DE: YAMANOUCHI PHARMACEUTICAL CO., LTD.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 31/00, A61K 31/18, A61K 31/54, A61K 31/5513, A61K 45/06, A61P 13/12, A61K 31/47,A61P 13/00

Ipc: C07D 223/16 (2011.01), C07D 401/12 (2011.01), C07D

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011.